Shanghai Pharmaceuticals (SHA:601607, HKG:2607) has been authorized to market Pregabalin capsules in Thailand after its unit, SHP Thailand, received a drug registration certificate from the country's drug administration, according to a Shanghai bourse disclosure on Friday.
The drug is primarily used for the treatment of postherpetic neuralgia, diabetic peripheral neuropathic pain, fibromyalgia, and neuropathic pain associated with spinal cord injury, as well as an adjunctive treatment for epilepsy, the Chinese pharmaceutical company said.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。